BioNTech (NASDAQ:BNTX) Trading Down 0.3% – Time to Sell?

BioNTech SE (NASDAQ:BNTX)’s stock price was down 0.3% during trading on Wednesday . The stock traded as low as $114.04 and last traded at $115.30. Approximately 65,586 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 810,809 shares. The stock had previously closed at $115.59.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research note on Monday. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft upped their price target on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Finally, Canaccord Genuity Group upped their price objective on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Price Performance

The firm has a fifty day moving average of $113.84 and a 200 day moving average of $99.36. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $28.49 billion, a P/E ratio of -56.59 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 earnings per share. On average, equities research analysts anticipate that BioNTech SE will post -3.72 EPS for the current year.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares during the period. Granite Bay Wealth Management LLC bought a new stake in BioNTech during the second quarter valued at approximately $1,483,000. Baader Bank Aktiengesellschaft increased its holdings in BioNTech by 4.2% during the second quarter. Baader Bank Aktiengesellschaft now owns 140,750 shares of the company’s stock valued at $11,258,000 after buying an additional 5,650 shares during the last quarter. LA Financiere DE L Echiquier increased its stake in shares of BioNTech by 9.5% in the 2nd quarter. LA Financiere DE L Echiquier now owns 234,539 shares of the company’s stock worth $18,848,000 after purchasing an additional 20,427 shares in the last quarter. Finally, Slow Capital Inc. raised its holdings in BioNTech by 12.0% in the 2nd quarter. Slow Capital Inc. now owns 51,080 shares of the company’s stock worth $4,105,000 after purchasing an additional 5,467 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.